Literature DB >> 10027405

Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.

N Johansson1, M Vaalamo, S Grénman, S Hietanen, P Klemi, U Saarialho-Kere, V M Kähäri.   

Abstract

Collagenase-3 (MMP-13) is a human matrix metalloproteinase specifically expressed by invading tumor cells in squamous cell carcinomas (SCCs) of the head and neck. Here, we have further elucidated the role of MMP-13 in tumor invasion by examining its expression in invasive malignant tumors of the female genital tract. Using in situ hybridization, expression of MMP-13 mRNA was detected in 9 of 12 vulvar SCCs, primarily in tumor cells, but not in intact vulvar epithelium, in cervical SCCs (n = 12), or in endometrial (n = 11) or ovarian adenocarcinomas (n = 8). MMP-13 expression was especially abundant in vulvar carcinomas showing metastasis to lymph nodes and was associated with expression of membrane type 1 MMP by tumor cells and gelatinase-A (MMP-2) by stromal cells, as detected by immunohistochemistry. MMP-13 mRNAs were detected in 9 of 11 cell lines established from vulvar carcinomas and in 4 of 6 cell lines from cervical carcinomas, whereas endometrial (n = 10) and ovarian (n = 9) carcinoma cell lines were negative for MMP-13 mRNA. No correlation was detected between MMP-13 expression and p53 gene mutations in vulvar SCC cell lines. However, MMP-13 expression was detected in 5 of 6 vulvar and cervical SCC cell lines harboring HPV 16 or 68 DNA. These results show that MMP-13 is specifically expressed by malignantly transformed squamous epithelial cells, including vulvar SCC cells, and appears to serve as a marker for their invasive capacity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027405      PMCID: PMC1849989          DOI: 10.1016/S0002-9440(10)65293-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  63 in total

1.  Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis.

Authors:  S T Nikkari; M Höyhtyä; J Isola; T Nikkari
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form.

Authors:  K Tamakoshi; F Kikkawa; A Nawa; H Ishikawa; K Mizuno; A Tamakoshi; S Yamagata; N Suganuma; Y Tomoda
Journal:  Cancer       Date:  1995-12-15       Impact factor: 6.860

3.  Immunohistochemical studies on matrix metalloproteinase-9 (MMP-9) and type-IV collagen in endometrial carcinoma.

Authors:  Y Inoue; K Abe; K Obata; T Yoshioka; G Ohmura; K Doh; K Yamamoto; H Hoshiai; K Noda
Journal:  J Obstet Gynaecol Res       Date:  1997-04       Impact factor: 1.730

4.  Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate.

Authors:  J Lohi; K Lehti; J Westermarck; V M Kähäri; J Keski-Oja
Journal:  Eur J Biochem       Date:  1996-07-15

5.  Different collagenase gene products have different roles in degradation of type I collagen.

Authors:  S M Krane; M H Byrne; V Lemaître; P Henriet; J J Jeffrey; J P Witter; X Liu; H Wu; R Jaenisch; Y Eeckhout
Journal:  J Biol Chem       Date:  1996-11-08       Impact factor: 5.157

6.  Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme.

Authors:  V Knäuper; H Will; C López-Otin; B Smith; S J Atkinson; H Stanton; R M Hembry; G Murphy
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

7.  72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study.

Authors:  M De Nictolis; S Garbisa; G Lucarini; G Goteri; L Masiero; A Ciavattini; G G Garzetti; W G Stetler-Stevenson; G Fabris; G Biagini; J Prat
Journal:  Int J Gynecol Pathol       Date:  1996-04       Impact factor: 2.762

8.  Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response.

Authors:  K J Heppner; L M Matrisian; R A Jensen; W H Rodgers
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

9.  Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.

Authors:  P G Mitchell; H A Magna; L M Reeves; L L Lopresti-Morrow; S A Yocum; P J Rosner; K F Geoghegan; J E Hambor
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.

Authors:  D Wernicke; C Seyfert; B Hinzmann; E Gromnica-Ihle
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

View more
  23 in total

Review 1.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 2.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

3.  Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression.

Authors:  Kaoru Yamagata; Xin Li; Shunkichi Ikegaki; Chitose Oneyama; Masato Okada; Michiru Nishita; Yasuhiro Minami
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

4.  Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis.

Authors:  Yasusei Kudo; Shinji Iizuka; Maki Yoshida; Takaaki Tsunematsu; Tomoyuki Kondo; Ajiravudh Subarnbhesaj; Elsayed M Deraz; Samadarani B S M Siriwardena; Hidetoshi Tahara; Naozumi Ishimaru; Ikuko Ogawa; Takashi Takata
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

5.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation.

Authors:  M T Salmela; T T MacDonald; D Black; B Irvine; T Zhuma; U Saarialho-Kere; S L F Pender
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor.

Authors:  Julie Lecomte; Anne Masset; Silvia Blacher; Ludovic Maertens; André Gothot; Marie Delgaudine; Françoise Bruyère; Oriane Carnet; Jenny Paupert; Martin Illemann; Jean-Michel Foidart; Ida K Lund; Gunilla Høyer-Hansen; Agnes Noel
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

7.  CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.

Authors:  Erica L Johnson; Rajesh Singh; Shailesh Singh; Crystal M Johnson-Holiday; William E Grizzle; Edward E Partridge; James W Lillard
Journal:  World J Surg Oncol       Date:  2010-07-22       Impact factor: 2.754

8.  MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma.

Authors:  Wiltrud Lederle; Bettina Hartenstein; Alice Meides; Heike Kunzelmann; Zena Werb; Peter Angel; Margareta M Mueller
Journal:  Carcinogenesis       Date:  2009-11-05       Impact factor: 4.944

9.  MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.

Authors:  Nikola Holtkamp; Isis Atallah; Ali-Fuat Okuducu; Jana Mucha; Christian Hartmann; Victor-F Mautner; Reinhard E Friedrich; Christian Mawrin; Andreas von Deimling
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

10.  Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer.

Authors:  M F Leeman; J A McKay; G I Murray
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.